TrialThe Lancet. Respiratory medicine2018

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.

Zhijie Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.